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Summary. Placental villous development requires the 
co-ordinated action of angiogenic factors on both 
endothelial and trophoblast cells. Like vascular 
endothelial growth factor (VEGF), VEGF-C increases 
vascular permeability, stimulates endothelial cell 
proliferation and migration. In the present study, we 
investigated the expression of VEGF-C and its receptors 
VEGFR-3 and VEGFR-2 in normal and intrauterine 
growth-restricted (IUGR) placenta. Immunolocalisation 
studies showed that like VEGF and VEGFR-l, VEGF-C, 
VEGFR-3 and VEGFR-2 co-localised to the syncytio-
trophoblast, to cells in the maternal decidua, as well as to 
the endothelium of the large placental blood vessels. 
Western blot analysis demonstrated a significant 
decrease in placental VEGF-C and VEGFR-3 protein 
expression in severe IUGR as compared to gestationally-
matched third trimester pregnancies. Conditioned 
medium from VEGF-C producing pancreatic carcinoma 
(Suit-2) and endometrial epithelial (Hec-lB) cell lines 
caused an increased association of the phosphorylated 
extracellular signal regulated kinase (ERK) in VEGFR-3 
immunoprecipitates from spontaneously transformed 
first trimester trophoblast cells. VEGF121 caused dose-dependant phosphorylation of VEGFR-2 in trophoblast 
cells as well as stimulating DNA synthesis. In addition, 
premixing VEGF165 with heparin sulphate proteoglycan 
potentiated trophoblast proliferation and the association 
of phospho-ERK with the VEGFR-2 receptor. VEGF16S-
mediated DNA synthesis was inhibited by anti-VEGFR-
2 neutralising antibody. The results demonstrate 
functional VEGFR-2 and VEGFR-3 receptors on 
trophoblast and suggest that the decreased expression of 
VEGF-C and VEGFR-3 may contribute to the abnormal 
villous development observed in IUGR placenta. 
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Introduction 
Establishment and development of the human 
placenta requires the co-ordinated proliferation and 
differentiation of both endothelial and trophoblast cells. 
The feto-placental vessels formed by the processes of 
vasculogenesis (Risau and Lemmon, 1988), and 
angiogenesis (Kaufmann et aI., 1985) ultimately give 
rise to the specialised gas exchange capillaries of the 
terminal villi, the functional unit of the placenta 
(Benirscbke and Kaufmann, 1995). This is essential for 
establishing a circulatory system that carries up to 40% 
of the fetal cardiac output towards the end of pregnancy 
(Eik-Nes et aI., 1980; Hendricks et aI., 1989). The 
successful development and function of the feto-
placental circulation is in turn dependant on the 
concurrent establishment of a functional trophoblast-
lined maternal-placental circulation in the intervillous 
space (Benirschke and Kaufmann, 1995). 
Impairment of these processes is thought to 
contribute to the condition intrauterine growth restriction 
(IUGR), a major cause of fetal morbidity and mortality. 
Elaborate ultrastructural and morphological studies of 
severe IUGR placenta with reduced or absent end-
diastolic flow velocity (AEDFV) show an aged 
syncytium and an impairment of angiogenesis with 
terminal villi displaying straight unbranched capillaries 
and erthrocyte congestion (Krebs et al., 1996; Macara et 
aI., 1996). These findings, together with the observation 
of higher maternal venous p02 in pregnancies 
complicated by IUGR (Pardi et aI., 1992), have led to 
360 
Decreased VEGF-C and VEGFR-3 in fUGR 
the suggestion that in IUGR, unlike preeclampsia, there 
is "placental hyperoxia" (Kingdom and Kaufmann , 
1997). It was subsequently proposed that increased 
oxygen levels surrounding the placental villi may limit 
angiogenesis as a result of disturbances in the expression 
and function of oxygen-sensitive angiogenic growth 
factors (Ahmed and Kilby, 1997). It should be noted, 
however, that changes in protein expression might also 
occur once the complication has developed. 
Nevertheless, we have shown that levels of placenta 
growth factor (PIGF) are elevated in IUGR placentae 
and that PIGF is upregulated by hyperoxia in vitro and 
that it inhibits endothelial but stimulates trophoblast 
proliferation (Khaliq et ai., 1999). Further confirmation 
comes from our recent study on angiopoetin-2, another 
angiogenic factor that was reported to be up-regulated by 
hypoxia (Oh et ai., 1999), showing that this factor is 
decreased in severe IUGR (Dunk et ai., 2000). 
Correlation of express and functional studies strongly 
suggests that the abnormal morphology observed in 
IUGR placentae may occur as a result of an early 
disturbance in the relative expression levels of 
angiogenic growth factors during the formation of the 
terminal villi. 
Vascular endothelial growth factor (VEGF) is an 
oxygen sensitive endothelial cell-specific mitogen and a 
potent angiogenic inducer of blood vessel formation 
(review, Ferrara and Davis-Smyth, 1997). In the human 
placenta, mRNA encoding VEGF (Sharkey et ai. , 1993) 
and VEGF receptor-1 (VEGFR-1/Flt-1) (Charnock Jones 
et ai., 1994) and their proteins (Ahmed et aI., 1995) are 
expressed by the macrophages of both fetal and maternal 
origin, endothelial cells and in villous cyto- and 
syncytiotrophoblast. As the terminally differentiated 
layer of syncytiotrophoblast (vasculosyncytial 
membrane) is in direct contact with maternal blood, it is 
assumed that they possess some endothelial functions in 
addition to their role as epithelial transporters. Indeed, 
stimulation of trophoblast VEGFR-1 is functionally 
coupled to endothelial nitric oxide synthase activation 
(Ahmed et ai, 1997). In more recent years, new separate 
gene product members of the VEGF family have 
emerged including VEGF-B, VEGF-C, VEGF-D and 
VEGF-E (review, Ortega et ai., 1998). 
Like VEGF, VEGF-C is able to increase vascular 
permeability and to stimulate the migration of bovine 
capillary endothelial cells in three-dimensional collagen 
gels (Joukov et aI., 1996, 1997). Functional studies have 
demonstrated that VEGF-C mediates Iymphangiogenesis 
stimulating lymphatic endothelial cell proliferation (Fitz 
et ai. , 1997; Oh et ai. , 1997). VEGF binds with high 
affinity to both VEGFR-1 (de Vries et ai. , 1992) and 
VEGFR-2/KDR (Millauer et ai., 1993) while VEGF-C 
binds to VEGFR-2 and VEGFR-3/Flt-4, displaying a 
preferential affinity for VEGFR-3 [KD = 135 pM] 
(Joukov et ai., 1996). Proteolytic processing of VEGF-C 
from a 32 kDa form to a mature 23 kDa form increases 
the interaction with VEGFR-2 [KD = 410 pM] (Kukk et 
ai. , 1996; Joukov et ai., 1997). To date the localisation of 
VEGFR-2 within the human placenta has been reported 
to be restricted to the feto-placental endothelial cells, 
where it is thought to promote angiogenesis (Barleon et 
ai. , 1994; Holt et ai. , 1997). Although VEGFR-3 is 
expressed on all early endothelial cells it becomes 
restricted to lymphatic endothelium during embryo-
genesis suggesting that VEGF-C mediates the formation 
of venous and lymphatic endothelium (Kaipainen et ai., 
1995; Kukk et ai., 1996). 
Relatively large amounts of VEGF-B and VEGF-C 
mRNA (Kukk et aI. , 1996), and two VEGFR-3 mRNA 
transcripts (Galland et ai., 1993) have also been 
identified in the placenta , though their expression 
patterns and function remain to be determined. The aim 
of this study was to identify the sites of expression of 
VEGF-C, VEGFR-2 and VEGFR-3 in human placenta 
and to further quantify the gestational changes in 
expression levels of VEGF-C and VEGFR-3 to make a 
comparison between severe IUGR and gestationally 
matched normal placenta. As these studies revealed that 
trophoblast in addition to endothelial cells, expressed 
VEGFR-2 and VEGFR-3 we investigated functionality 
of these receptors in stimulating trophoblast proliferation 
using in vitro assays and a stable trophoblast cell line. 
Materials and methods 
Tissue collection 
First trimester placental tissues (FT, 7-12 weeks 
gestation; n=l1) were collected from surgical 
termination of pregnancies. Third trimester (3T, 27-36 
weeks gestation; n=5) and uncomplicated term placenta 
(Term NL 38-42 weeks gestation; n=14) delivered by 
elective Caesarean section for breech presentation or a 
recurring indication in otherwise uncomplicated 
pregnancies were collected as non-labouring tissues. 
Labouring term placenta (Term Lab , 38-42 weeks 
gestation; n=12) were obtained from uncomplicated 
vaginal deliveries. In addition non-labouring tissues 
were also collected by elective Caesarean section from 
pregnancies complicated by IUGR (IUGR, 28-36 weeks 
of gestation; n=lO) or preeclampsia (PE, 28-37 weeks 
gestation; n=10). For analysis these placenta were 
compared with the gestationally matched normal non 
labouring third trimester group. Placental tissues for 
IUGR were obtained from women with absent end 
diastolic flow velocity (Hanretty et ai., 1989) and small 
for date babies with fetal weight < 5th centile for 
gestational age. Preeclampsia was diagnosed when blood 
pressure was at least 140/90 mmHg or greater in a 
previously normotensive woman after 20 week 
gestation, and that there was at least 300 mg/ day 
proteinuria, platelet count < 150,000/ml and urate> 350 
mmol/I (Sibai, 1991). At least two such blood pressure 
recordings were obtained on consecutive occasion's four 
hours apart. All subjects in the preeclampsia group were 
investigated in the puerperium to ensure that they were 
normotensive with no significant proteinuria at twenty 
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weeks post-delivery. Placental tissues were collected 
from a central location lying between the basal and 
chorionic plates and were the full thickness of the 
placenta. Amnion and chorion (chorionic laeve) were 
collected from each placenta from reflected membranes 
formerly covering the decidua parietalis of the uterus. A 
section of umbilical cord was also collected from each 
delivery. Cervical biopsies were also collected as a 
control tissue from non-pregnant patients undergoing 
investigative procedures. Tissues were immersed in 10% 
formaldehyde, embedded in paraffin wax and processed 
for immunocytochemistry (3 ,urn sections), or snap 
frozen in liquid nitrogen immediately after collection 
prior to homogenisation. Ethical committee approval for 
tissue collection was obtained from the South 
Birmingham Ethical Committee. 
Antibodies 
Rabbit polyclonal VEGFR-l/(Flt-1) (C-17), rabbit 
polyclonal VEGFR-2/ (f1k-l/KDR) (C-1158) , rabbit 
polyclonal VEGFR-3/(Flt-4) (C-20) and goat polyclonal 
VEGF-C (C-20) antibodies were purchased from Santa 
Cruz Biotechnology (Autogen Bioclear, Steven age, UK). 
These antibodies are raised against sequence specific 
peptides and demonstrate no cross reactivity between 
VEGFR-1 , VEGFR-2 and VEGFR-3 or VEGF, VEGF-B 
and VEGF-D respectively. VEGFR-2 and VEGF-C 
western blots were run against control recombinant 
proteins VEGFR-2 (Flk 1158-1345), VEGF-C (sc-1881 
P) (Autogen Bioclear). Anti-human mouse monoclonal 
cytokeratin and macrophage CD68 were purchased from 
Dako limited (Dako Ltd, Bucks, UK). 
Immunohistochemistry 
Immunohistochemistry for VEGFR-3 and VEGF-C 
was carried out in normal term non labouring placenta. 
Immunohistochemistry was carried out to localise 
VEGFR-2 in normal first trimester (n=5) and term non 
labouring (n=6), preeclamptic (n=6) and IUGR placentae 
(n=6). Serial 3 ,urn sections of formalin-fixed, paraffin-
embedded placental tissues were used for immuno-
histochemistry as described in detail (Ahmed et aI. , 
1995). Briefly, sections were deparaffinized and 
hydrated. Sections were pre-treated by microwave in 
10mM citrate buffer, 0.1 % EDTA (pH 6.0) for 30 
minutes. Endogenous peroxidase activity was quenched 
by the incubation in 0.3% (v/v) of hydrogen peroxide in 
methanol for 10 minutes. Sections were either incubated 
with anti-VEGFR-2 primary antibody (l,ug/ml) or anti-
VEGFR-3 primary antibody (2,ug/ml) or anti-VEGF-C 
primary antibody (4,ug/ml) in 5% milk solution for 60 
minutes. Amplification of the primary antibody reaction 
was achieved using a biotinylated goat anti-mouse/rabbit 
secondary antibody or a biotinylated anti-goat secondary 
antibody for 30 minutes followed by a complex of 
streptavidin and biotinylated peroxidase (DAKO Ltd, 
Bucks., UK) for a further 30 minutes. Finally, binding 
was visualised by incubating the sections with 0.5 mg/ml 
diaminobenzidine (Sigma Chemical Co. Ltd, Poole, 
Dorset, UK) and 0.01 % hydrogen peroxide in PBS for 5 
minutes. Between each step the sections were washed in 
3x200 ml of PBS for 5 min. All incubations of antiserum 
were carried out at room temperature in a wet chamber. 
Sections were counterstained with Mayers Haematoxylin 
(Raymond A Lamb, London, UK) , dehydrated and 
mounted. Control sections were performed in duplicate 
tissues for each antibody where the primary antibody 
was replaced with 10% non-immune goat serum. 
Additional controls for the VEGF-C and VEGFR-2 
antibodies were performed where antibodies were pre-
absorbed with 100-fold excess control peptides provided 
by Autogen Bioclear. Serial sections were also stained 
with anti-human mouse monoclonal cytokeratin and 
macrophage CD68 antibodies to identify specific cell 
type. 
Western Blotting 
Proteins were extracted from first trimester (FT, 
n=4), third trimester (3T, n=4), term non-labouring (NL, 
n=5) , and labouring (Lab, n=5), intrauterine growth 
retarded (IUGR, n=5) , and preeclamptic (PE, n=5) 
placenta and subjected to Western blot analysis as 
previously described (Ahmed et aI., 1997). Briefly, 
extracted protein was resuspended in 2xSDS sample 
buffer and boiled for 5 minutes. Equal amounts of total 
protein (100,ug) was separated on a 10% polyacrylamide 
gel by electrophoresis, and transferred to nitrocellulose 
membranes (Amersham, Bucks., UK) at room 
temperature, overnight. Membranes were blocked with 
1 % milk fat (Premier Beverages, Staffs., UK) in Tween 
tris buffered saline (TIBS: 10mM Tris pH7.5, 100mM 
NaCI, 0.1 % Tween 20) for 6 hours at room temperature, 
washed in TIBS at room temperature for 15 minutes, 
and the wash repeated twice for 5 minutes. Membranes 
were incubated with either anti- VEGF-C antibody 
(0.2,ug/ml) or anti-VEGFR-3 antibody (O .l,ug/ml) at 
4 °C, overnight. Membranes were washed and antibody 
reactions were detected using the ECL detection kit 
(Amersham, Bucks., UK), followed by detection of 
chemiluminescence on X-ray film. Intensity of detected 
bands was quantified by laser densitometry (LD) and 
presented as LD units. 
Cell culture 
A first trimester spontaneously transformed stable 
trophoblast cell line ED27 , generated by repeated 
passaging of trophoblast obtained from first-trimester 
chorionic villi by chorionic villous sampling (Diss et aI., 
1992), was used to assess effects of VEGF and VEGF-C. 
The ED 27 cell line has been characterised and 
demonstrated to express the alpha and beta subunits of 
human chorionic gonadotrophin , placental alkaline 
phosphatase, and cytokeratin peptide-8 but not vimentin 
and factor VlII (Kniss et aI. , 1994). All passages used in 
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experiments exhibited phenotypic features consistent 
with cytotrophoblast. 
Preparation and stimulation of cells 
The first trimester ED27 trophoblast cell line was 
maintained in T25 flasks in a 1: 1 mixture of 
DMEM/HAMS F-12 containing 15 % FCS, 1 % L-
Glutamine and 1 % antibiotic mixture (5000 IU/ml 
penicillin and 5000,ug/ml streptomycin) at 37 °C 5% 
CO 2, 95 % humidity . Cells were grown to 80% 
confluence and the medium replaced with serum free 
DMEM / F-12 for 24 hours . For assessment of the 
presence of functional VEGFR-2, cells were stimulated 
with increasing concentrations of VEGF121 or VEGF165 (Strahmann Biotech, Hannover, Germany) either alone 
or premixed with heparin sulphate proteoglycan (HSPG) 
(l,ug/ml) (Sigma). For the assessment of the presence of 
functional VEGFR-3 , cells were stimulated with 
conditioned medium from the human carcinoma cell 
lines Hec1-B and Suit-2. All experiments were 
performed on three independent occasions and in 
triplicate wells on each occasion. 
Autophosphorylation of VEGFR-2 and VEGFR-3 in 
trophoblast cells 
The first trimester trophoblast cell line ED27 was 
prepared and stimulated as described above. Controls of 
unstimulated cells were also carried out with serum free 
medium containing 0.2% BSA. Following incubations 
flasks were washed with ice cold PBS and protein was 
extracted by addition of 0.5ml immunoprecipitation 
buffer and precipitations carried out as described 
previously (Ahmed et aI. , 1997). Briefly lysates were 
precleared and protein concentrations were determined 
by the Biorad protein assay. Anti- VEGFR-1 , anti-
VEGFR-2, or anti-VEGFR-3 antibodies were added to 
respective experiments as indicated (l,ug/ml) , and 
incubated overnight at 4 °C on an orbital shaker. The 
immunocomplex was captured by addition of Protein-A 
4 % beaded agarose, washed three times with 
immunoprecipitation buffer and resuspended in 50,u1 of 
2x sample buffer, prior to SDS-PAGE performed on 25 
,ul of each sample. Proteins were transferred to a 
nitrocellulose filter and phosphorylated bands visualised 
by incubation of the filter with monoclonal anti-
phosphotyrosine PY20 (0.5 ,ug/ml) (Affinity Research 
Products Limited, Exeter, UK) for one hour at room 
temperature. Association of the phosphorylated mitogen 
activated kinase (MAP) kinase ERK was assessed by 
western blotting of VEGFR-1, VEGFR-2 or VEGFR-3 
immunoprecipitates with an anti-phospho-ERK antibody 
(0.025,ug/ ml) (New England Biolabs , Hitchin, 
Hertfordshire, UK). The non radioactive ECL Western 
Blotting System (Amersham International pIc, Bucks, 
UK) was used to detect phosphorylated bands associated 
with the VEGF receptors. Results are expressed as a 
representative of three independent experiments. 
PH] thymidine incorporation. 
ED27. cells were seeded in 24 well plates in growth 
medium (DMEM/F-12 15% FCS) at a density of 30,000 
cell per well and grown to 70-80% confluence. Cells 
were rendered quiescent by incubation for 24 h in 
DMEM/ F-12 0.2 % BSA. VEGF165 both alone and 
premixed with HSPG (1 ,ug/ml) was added to the cells at 
increasing concentrations (1-50 ng/ml) and incubated for 
30 h. During the last 6 h of the 30 h incubation with 
VEGF, cells were labelled with [methyl-3H] thymidine 
at 0.2 ,uCi / ml (Amersham lnt. pic). Following 
completion of the incubation cells were washed with 
PBS, fixed in 5% ice cold TCA, and washed with 100% 
ethanol. Cells were lysed in PBS, 0.2% BSA, 1% Triton 
X-100 and 1mM NH 40H and incorporated [3H]-
thymidine measured by B-scintillation counter. Cell 
proliferation was assessed over a 48 h time period under 
the same stimulatory conditions by counting cell 
numbers in a standardised Coulter counter (Coulter 
electronics, Harpenden, Herts., UK) with the lower 
threshold level set to 14. Results are expressed as a mean 
of three independent experiments (mean±S .D) each 
performed in triplicate determinations and were analysed 
by student t-test. 
Results 
Expression of VEGFR-3 and VEGFR-2 proteins by 
human placenta 
To investigate specificity of the anti-VEGF receptor 
antibodies used total protein from first trimester and 
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Fig. 1. Identification of the VEGFR-3 and VEGFR-2 receptors in 
placental extracts. Placental proteins were immunoprecipitated with 
either an anti-VEGFR-3 (A) or anti-VEGFR-2 antibody (1 J.1g/ml) followed 
by SDS PAGE and Western blotting with either anti-VEGFR-3 (A) or 
anti-VEGFR-2 (8) antibody (0.1 J.1g/ml) against a recombinant VEGFR-2 
(Flk-1158-1345) positive control. A. VEGFR-3 immuno-precipitates from 
first trimester (FT) and Term Labouring (TL) placental. and cervix (Cx) 
proteins display a specific 170kDa band. No band was detected in the 
VEGFR-2 Flk-1158-1345 positive control. B. VEGFR-2 Immuno-
precipitates from first trimester (FT) . Term Labouring (TL) placental and 
cervix (Cx) proteins display a specific 210 kDa band corresponding with 
the recombinant Flk-1158-1345 VEGFR-2 protein. 
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term placenta were immunoprecipitated overnight with 
either an anti-VEGFR-3 or anti-VEGFR-2 antibody (1 
,ltg/ml). Immunoprecipitates were separated by SDS-
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PAGE and run against a recombinant VEGFR-2 protein 
(Flk-1158-1345) as positive control followed by Western 
blotting with the anti- VEGFR-3 or anti- VEGFR-2 
'" :-.: 
" 
Fig. 2. Immunolocalisation of VEGF·C in normal human term placenta. A. Immunostaining for VEGF-C was detected in the endothelial cells of the large 
blood vessels in stem villi (bv) and in isolated cytotrophoblast (c) . B. Moderate VEGF-C immunostaining of the syncytiotrophoblast of the smaller 
terminal villi (syn) . C. The maternal decidua (dec) displays variable immunostaining for VEGF-C with some macrophage cells more strongly positive 
than others (me) . There is no staining of the extra villous trophoblast, identified by strong cytokeratin immunostaining (not shown here) . D. The amnion 
(amn) and chorion (chor) show moderate staining for VEGF-C. E. Control sections incubated with the primary antibody preabsorbed with excess control 
peptide showed no immunostaining. F. Control sections incubated without the primary antibody showed no immunostaining. A, D, x 560; B, C, E, F, 
x 280 
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antibody (0.1 ,ug/ ml). Placental protein VEGFR-3 
immunoprecipitates demonstrate a specific 170 kOa 
band in both first trimester and term placenta (Fig. lA) 
and is in agreement with previously published report 
(Galland et aI., 1993). No band was detected with anti-
VEGFR-3 in the VEGFR-2 fusion protein Flk-1l58-
1345 used as VEGFR-2 positive control, while cervix 
protein displayed the 170 kOa band confirming 
specificity of the anti-VEGFR-3 antibody (Fig. 1A) 
(Sisi, 1997). In contrast, VEGFR-2 immunoprecipitates 
display a specific band of 210 kDa in first trimester, term 
placenta and cervix (Fig. 1B). This molecular weight 
corresponds to the band detected in the VEGFR-2 
positive control and agrees with previous reports 
(Waltenberger et aI., 1994, Thieme et aI. , 1995). These 
studies confirm specificity and non-cross reactivity of 
the anti-receptor antibodies used in this study. 
Immunolocalisation of VEGF-C in the placenta 
Weak VEGF-C immunoreactivity was observed in 
the endothelial cells of the larger vessels (bv) of the stem 
villi (Fig. 2A). VEGF-C immunostaining was detected in 
varying intensity in the syncytiotrophoblast (syn) of term 
placental villi (Fig. 2B) and also in isolated 
cytotrophoblast (c) (Fig. 2A). The smaller terminal villi 
displayed stronger staining than the larger mature 
primary and secondary stem villi (Fig. 2B) however no 
staining was detected in the capillaries of the terminal 
villi (cap). The maternal decidua (dec) also displayed 
moderate to weak VEGF-C immunostaining with 
maternal macrophage cells (m0) more strongly positive 
(Fig. 2C). The extra villous trophoblast layer lining the 
decidua, identified by positive cytokeratin staining in 
serial sections (data not shown) showed no staining for 
VEGF-C. Moderate VEGF-C staining was also observed 
in the vascular chorion (chor) and the avascular amniotic 
epithelium (amn) in term placenta (Fig. 20). No positive 
staining was observed when the antiserum was pre-
absorbed by excess of VEGF-C control peptide or when 
the primary antibody was replaced with non-immune 
serum (Fig. 2E,F). 
Immunolocalisation of VEGFR-3 in the placenta 
VEGFR-3 protein expression in the human placenta 
localised to endothelial cells of arterial, venous and 
capillary blood vessels (bv) (Fig. 3A). Strong VEGFR-3 
immunostaining was observed in the endothelial cells of 
the large placental vessels, and surrounding the veins of 
the mature stem villi (v) (Fig. 3B). The endothelial cells 
of the smaller placental capillaries (cap) demonstrated 
more moderate VEGFR-3 immunostaining (Fig. 3A). 
The large umbilical vessels, both artery and vein, also 
stained strongly for VEGFR-3 (data not shown). More 
interestingly, the highest level of immunostaining for 
VEGFR-3 was detected in the syncytiotrophoblast of the 
terminal villi, the functional gas exchange unit of the 
placenta (Fig. 3C). The trophoblastic staining 
demonstrated a decrease in intensity from the terminal to 
the mature stem villus. The maternal decidua (dec) also 
demonstrated strong immunostaining for VEGFR-3 
though the invasive extravillous trophoblast, identified 
by positive cytokeratin staining in serial sections of the 
same tissue (data not shown), showed no staining (Fig. 
3D). Term placental chorionic (chor) and amniotic (amn) 
epithelial membranes the also displayed strong VEGFR-
3 immunostaining (Fig. 3E). No positive staining was 
observed when the antiserum was replaced with non-
immune serum, or (Fig. 3F). 
Immunolocalisation of VEGFR-2 in healthy and 
complicated placentae 
This study demonstrated very intense VEGFR-2 
immunostaining in the terminally differentiated 
syncytiotrophoblasts (syn) (Fig. 4) of placental villi, and 
in the invasive extravillous trophoblasts (evt) 
(cytokeratin positive, data not shown) of normal term 
placenta (Fig. 4B). Furthermore, immunoreactive 
VEGFR-2 was also detected in trophoblast cells isolated 
from term placenta and a first trimester trophoblast cell 
line E027 cytospun onto a microscope slide (data not 
shown). Intense immunostaining for VEGFR-2 was 
present in the Hofbauer cells (h) of term placental villi 
(Fig. 4A), identified by positive immunostaining with 
anti C068 antibody. Maternal decidual cells (dec) 
(negative for cytokeratin and C068) also stained 
strongly for VEGFR-2 (Fig. 4A). Strong expression of 
VEGFR-2 immunoreactive protein was detected in the 
endothelium of the major blood vessels in mature stem 
villi (Fig. 4D), with a weaker staining apparent in the 
paravascular capillary network of the stem villi and 
capillary endothelium of the terminal villi (cap) (Fig. 
4C). Interestingly, the pattern and intensity of the 
VEGFR-2 immunostaining in the placental sections from 
pregnancies complicated by preeclampsia (Fig. 40) or 
IUGR (Fig . 4E) showed no obvious difference from 
normal term placenta. No positive staining was observed 
when the primary antibody was replaced with non-
immune serum, or when the antiserum was pre-absorbed 
by excess of the Flk-1l58-1345 control peptide (Fig. 
4F). 
Expression levels of VEGF-C protein in placentas from 
healthy and complicated pregnancies 
We next investigated the expression levels of VEGF-
C protein in placenta throughout gestation and in 
placenta complicated by IUGR and preeclampsia. Semi-
quantitative western blot analysis of VEGF-C protein 
levels in the placenta demonstrated a major 23 kOa 
protein corresponding to the control VEGF-C protein in 
all samples (Fig. 5A), a second 32 kOa protein was 
detected in some samples. The size of the bands detected 
correspond with reported sizes for VEGF-C (Kukk et aI., 
1996) and provide confirmation of the specificity of the 
anti-VEGF-C antibody. Laser densitometric analysis of 
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the 23 kDa band demonstrated that levels of VEGF-C 
protein were highest in first trimester (white bar) and 
third trimester (grey bar) placenta and decreased to 
term in non labouring placentae (grey hatched bar) 
(Fig. SB). Interestingly, at term the levels of VEGF-C 
demonstrated a highly significant 2 fold increase in band 
intensity in labouring placenta (black hatched bar) 
as compared to non-labouring placenta (p<O.OOOl, 
Fig. 3. VEGFR-3 immunostaining in normal human term placenta. A. Moderate immunostaining for VEGFR-3 is detected in the endothelial cells of the 
large vessels of the stem villi (bv) with weaker staining apparent in the smaller capillaries (cap). B. Intense immunostaining for VEGFR-3 localises to 
the surrounding venous tissues (v). C. The syncytiotrophoblast of the terminal villi show intense immunostaining for VEGFR-3 (syn). D. The maternal 
decidua demonstrates strong staining for VEGFR-3 (dec) There is no staining of the extra villous trophoblast identified by strong cytokeratin 
immunostaining (not shown here) . E. Strong immunostaining for VEGFR-3 in the avascular amnion (amn) and vascular chorion (chor). F. Control 
sections incubated with non specific goat serum show no immunostaining. A, D, F, x 280; B, C, x 560 
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Fig. 4. VEGFR-2 immunostaining in placentae from normal and preeclamptic and IUGR pregnancy. (A-C) 38 weeks gestation. A. Very intense 
immunostaining for VEGFR-2 is demonstrated in the vasculosyncytial membrane, maternal decidual cells (dec) and fetal hoefbauer cells (h) . B. Intense 
immunostaining for VEGFR-2 is also detected in the extravillous trophoblast (evt) identified by cytokeratin immunostaining (not shown here). 
C. Vascular endothelial cells of blood vessels (bv) within placental villi show moderate immunostaining for VEGFR-2. D and E. There is no change in 
immunostaining intensity or distribution for VEGFR-2 in PE (panel D, 36 week gestation) or IUGR (panel E 35 week gestation) sections. F. Control 
sections incubated without the primary antibody showed no immunostaining. A-C, x 280; D-F, x 560 
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Fig. 5. VEGF-C protein levels are decreased in IUGR placenta. Semi 
quantitative western blot analysis of VEGF-C in protein extracts from 
placentae collected from first trimester (FT, white bar, n=4) , third trimester 
(3T, grey bar, n=4) , term non-labouring (NL, grey hatched bar, n=5), 
labouring (Lab, black hatched bar, n=5) , intrauterine growth restricted 
(IUGR, black bar, n=5) and preeclamptic (PE, spotted bar, n=5) deliveries. 
A. The anti-VEGF-C antibody (0.2 J,Jg/ml) recognised a major band at 23 
kDa corresponding to the VEGF-C control protein in protein extracts from all 
placentae and a 32 kDa band in some samples. B. Data is presented as 
Laser Densitometric (LD) analysis of the major 23 kDa band and 
demonstrates a significant decrease throughout gestation and in IUGR and 
PE placentae as compared to gestationally matched 3T placentae. In 
addition a maximal highly significant 2-fold increase in intensity of VEGF-C 
was detected in labouring term placenta as compared to non labouring term 
placenta. Statistical analysis on the intensity of bands was performed using 
Student unpaired t-test. *: p<0.05; **: p<0.01 ; ***: p<0.0001 in comparison 
to control 3T placenta. 
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Fig. 6. VEGFR-3 protein levels are decreased in IUGR placenta. Semi 
quantitative western blot analysis of VEGFR-3 in protein extracts from 
placentae collected from first trimester (FT, white bar, n= 4), pre-term third 
trimester (3T, grey bar, n=4), term non-labouring (NL, grey hatched bar, 
n=5) , labouring (Lab, black hatched bar, n=5), intrauterine growth restriction 
(IUGR, black bar, n=5) and preeclampsia (PE, spotted bar, n=5) deliveries. 
A. Major bands for VEGFR-3 at 100 and 70 kDa were detected in protein 
extracts from all placentae and in the positive control tissue Cervix (Cx) by 
the anti-VEGFR-3 antibody (0.1 J,Jg/ml) (Sisi , 1997). B. Laser Densitometric 
analysis of the 100 kDa band demonstrated a Significant decrease in band 
intensity throughout gestation and in IUGR placentae as compared to 
maximal levels as detected in gestationally matched 3T placentae. A small 
increase in intensity was detected in labouring term placenta as compared to 
non labouring term. Statistical analysis on the intensity of bands was 
performed using Student unpaired t-test. *: p 0.05, **: p<0.01 in comparison 
to control 3T placenta. 
protein levels as compared to gestationally matched t 
hird trimester placenta (p <O.OOl vs 3T, n=5, Fig. 
5B). 
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Expression levels of VEGFR-3 protein in placentas from 
healthy and complicated pregnancies 
Western blot analysis of VEGFR-3 placenta l protein 
levels with the anti-VEGFR-3 antibody identified two 
major bands of 100 and 70 kDa in the human placenta 
throughout gestation (Fig. 6A). The two bands detected 
can be attributed to the reducing conditions present in 
the assay wh ich reduce di s u lph ide bond s . Laser 
densitom etric ana lysis of protein leve ls throughout 
gestation demonstrated a high level of VEGFR-3 protein 
in first trimester (white bar) and third trimester placenta 
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Fig. 7. Autophosphorylation of trophoblast VEGFR-3. A. Western blot analysis of tumour cell condiiioned medium (CM) for the presence of VEGF-C. 
Blot was probed with anti-VEGF-C antibody (O.2IJg/ml) and demonstrated a single band of 23 kDa corresponding to the control VEGF-C protein. 
B. Trophoblast cells were incubated with DMEM/F-12 0.1 %FCS (Lane 1 ), 15%FCS (Lane 2) Hec-1 B CM (Lane 3) or Suit-2 CM (Lane 4) for 2 hours at 
37 °C. Cell extracts were immunoprecipitated with anti-VEGFR-3 antibody (1 pg/ml) overnight followed western blot analysis with PY20 anti-
phosphotyrosine antibody (0.5 pg/ml) . A single phosphorylated band of 42kDa was observed in all cases. Laser densitometric analysis demonstrated 
an increase in intensity of the 42 kDa band on addition of 15%FCS or Suit-2 CM. C. Identification of the 42 kDa band as phospho-ERK. The blot from 
panel B was stripped and reprobed with anti-phospho-ERK antibody (0.025 pg!ml) identifying the 42 kDa phospho-protein associated with VEGFR-3 
immunoprecipitates as phosphorylated ERK. Laser densitometric analysis demonstrated a 189% increase in ERK band intensity on stimulation with 
Suit-2 CM. 
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(grey bar) (Fig. 6B). As gestation progresses to term 
VEGFR-3 protein levels show a significant decrease in 
expression (p<O.OS, n=S). However, a small increase in 
labouring term placenta (black hatched bar) was 
observed, as compared to non labouring term placenta 
(grey hatched bar) , obtained by elective caesarean 
section. Placenta from pregnancies complicated by 
IUGR (solid bar) displayed a significant decrease in 
VEGFR-3 protein levels, as compared to gestationally 
matched third trimester placenta (p<0.01 vs 3T, n=S) 
A VEGF165 (ng/ml) 
I C 0.1 1 10 20 I 
87 -
44-
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Fig. 8. Autophosphorylation of VEGFR -2 in human trophoblast. 
Stimulation's were initiated by the addition of increasing concentrations 
of 0.1-20 ng/ml VEGF165 (Lanes 2-5) or VEGF121 (Lanes 7-10) and a 2 
hour incubation at 37 ·C. Cell extracts were immunoprecipitated with 
anti-VEGFR-2 antibody (1 J.lg/ml) overnight followed western blot 
analysis with PY20 antiphosphotyrosine antibody. VEGF165 has little 
effect above control levels of phosphorylated bands detected at 210, 
130 and 120 kDa. VEGF121 causes a dose dependant increase above 
control levels of the 210 and 120 kDa phosphorylated bands. 
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(Fig.6B). 
Activation of VEGFR-3 and association of phospho-ERK 
In this study we further demonstrate the presence of 
functional VEGFR-3 in first trimester trophoblast (Fig. 
7). As tumour cell lines were reported to secrete VEGF-
C (Joukov et ai., 1996) we first investigated the presence 
of VEGF-C in conditioned media (CM) from a human 
endometrial epithelial adenocarcinoma cell line, (Hec-
1B) or a pancreatic carcinoma cell line, (Suit-2). Western 
blot analysis of the Hec-1B and Suit-2 CM displayed a 
single 23 kDa band corresponding to the control VEGF-
C protein (Fig. 7A). Next, to investigate the activation of 
trophoblastic VEGFR-3 quiescent first trimester 
trophoblast ED27 cells were stimulated for 2 hours with 
conditioned media (CM) obtained from the carcinoma 
cell lines or 1S % FCS. Cell lysates were immuno-
precipitated with anti-VEGFR-3 antibody (O .S ,uglml) 
and tyrosine kinase phosphorylation was assessed using 
a monoclonal anti-phospho tyrosine kinase antibody PY-
20. A single phosphorylated band of 42 kDa associated 
with the VEGFR-3 in the control (Lane 1; 0.1 % FCS) 
(Fig. 7B). On stimulation with lS% FCS (Lane 2) or 
conditioned media obtained from Suit-2 cells (Lane 4) 
(Fig. 7B,Bi) there was an increase in band intensity of 
2S % and 39 % respectively as assessed by laser 
densitometric analysis. Hec-1B cell conditioned media 
caused no increase in intensity of the phosphorylated 
band (Lane 3). The 42 kDa phosphoprotein associated 
with VEGFR-3 immuno-precipitates was further 
identified by stripping and reprobing of the blot with a 
specific anti-phospho-ERK antibody demonstrating an 
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Fig. 9. Effect of VEGF l65 alone and premixed with HSPG on trophoblast proliferation. Quiescent trophoblast cells were incubated with VEGF l65 or 
VEGF165+HSPG in increasing concentrations 1-50 ng/ml for 24 hours, and DNA synthesis and cell numbers determined as described in materials and 
methods. A. Addition of VEGF165 alone (solid bars) had little effect on PH) thymidine incorporation causing a small significant increase (p<0.05, n=3) 
above control at 5 ng/ml alone and B. had no effect on cell number. A. Addition of VEGF165 premixed with HSPG (hatched bars) caused a significant 
increase in [3H] thymidine incorporation at all doses with the maximal response observed at 5 ngjml stimulating a 2.5 fold increase in DNA synthesis 
(p<0.001 , n=3) B: and an increase in cell number (p<0.05, n=3). Addition of HSPG (40 ngjml) had no effect on trophoblast DNA synthesis or cell 
number. Data is expressed as a mean±S.D. of three independant experiments performed in triplicate determinations per experiment. Statistical analysis 
was performed using the students unpaired t test . *: p<0.05; **: p< 0.001 , n=3 as compared to control. 
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increase in band intensity on stimulation with Suit-2 CM 
(189%, Lane 4) (Fig. 7C,Ci). This band corresponds to 
the previously reported size of ERK-2 (review, Karin, 
1995). 
Tyrosine kinase activation of VEGFR-2 by VEGF121 and 
VEGF165 
We further demonstrate the presence of functional 
VEGFR-2 receptor in the human first trimester 
trophoblast ED27. Quiescent cells were stimulated with 
increasing concentrations of VEGF121 or VEGF165 (ng/ml) and cell lysates prepared. Following immuno-
precipitation with anti-VEGFR-2 antibody, tyrosine 
kinase phosphorylation was assessed as above. VEGFR-
2 immunoprecipitates display major phosphorylated 
bands detected at 210 kDa, 130, and 120 kDa that were 
present in both control and stimulated cells (Fig. 8). 
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induced a dose-dependent increase in the phospho-
rylation of the 210 kDa VEGFR-2 with maximal 
phosphorylation observed at 20 ng/ml. In contrast 
stimulation of the cells with VEGF165 had little effect on 
VEGFR-2 phosphorylation above control levels (Fig. 8). 
VEGF165 premixed with heparin sulphate proteoglycan (HSPG) stimulates trophoblast proliferation 
We have previously reported that the addition of 
VEGF165 to first trimester human trophoblast does not 
increase DNA synthesis in a reproducible manner 
though it increases VEGFR-1 phosphorylation (Ahmed 
et al., 1997). Here, we furtber investigate the potential 
sequesterisation of VEGF165 by VEGFR-1 and native 
HSPG present in the trophoblast cell membrane or the 
extracellular matrix (ECM) as has been demonstrated in 
an extravillous trophoblast cell line (Athanassiades et al., 
1998). This possibility was tested by premixing 
VEGF165 with excess (l,ug/ ml) so luble HSPG's , 
saturating the heparin binding sites prior to stimulation 
of the cells and a 30 hour incubation at 37 °C. DNA 
synthesis was assessed over the last 6 hours of 
incubation by the addition of [3H] thymidine (0 .2 
,uCi/ml). The addition of increasing doses of VEGFtQ~ 
alone (solid bars) stimulated a small increase in [3HJ 
thymidine incorporation above basal control levels 
(white bar). In all cases, VEGF165 mediated DNA 
synthesis was below that of epidermal growth factor (2 
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Fig. 10. VEGF stimulates trophoblast proliferation through VEGFR-2. A. Quiescent trophoblast were stimulated with 10 ng/ml VEGF,65 premixed with 
HSPG (solid bar) and in the presence of increasing concentrations (10-30 ng/ml) of a neutralising antiVEGFR-2 antibody (hatched bars) . Blockage of 
VEGFR·2 inhibited VEGF stimulated DNA synthesis in a dose dependant manner (p<O.OOl , n=3). Statistical analysis was performed using the students 
unpaired t test. *: p<0.05; **: p< 0.001 , n=3 as compared to control. Band C. Premixing VEGF165 with HSPG potentiates the association of phospho-
ERK-2 with VEGFR-2. Quiescent trophoblast were stimulated with VEGF165 (10-25 ng/ml), alone (lanes 2, 3, 8 and 9, B) and in the presence of 
excess HSPG (lanes 4, 5, 10, and 11 B) as in Fig 9. HSPG alone (40 ng/ml) was used as a control (lanes 6 and 12). Incubations were carried out for 2 
hours at 37 ·C prior to ex1raction of total cell proteins and immunoprecipitation with either anti-VEGFR-l (lanes 1-6) or anti-VEGFR-2 (lanes 7-12) 
antibodies as described in Materials and methods. B: The association of activated ERK with VEGFR-l (lanes 1-6) or VEGFR-2 (lanes 7-12) was 
assessed by immunoblotting with a polyclonal anti-phospho ERK antibody (0.025 tJg/ml) demonstrating a specific 42 kDa band in all samples. C: Laser 
Densitometric analysiS of the 42 kDa band demonstrated an increase in phospho-ERK-2 in VEGFR-l immunoprecipitates (solid bars) on stimulation 
with VEGF,65 alone (lanes 2 and 3 A) . In contrast VEGFR-2 immunoprecipitates (hatched bars) demonstrate an increase in ERK band intenSity on 
stimulation with VEGF,65 in the presence of HSPG (lanes 10 and 11 A). Data shown is representative of three independant experiments each showing 
a similar profile. 
371 
Decreased VEGF-C and VEGFR-3 in IUGR 
ng/ ml, black spotted bar) and variability between 
experiments high (Fig. 9A). In contrast, VEGF165 
premixed with HSPG (hatched bars) significantly 
stimulated [3H] thymidine incorporation in a dose-
dependant manner (Fig. 9A) while HSPG alone (40 
ng/ml) had no effect. Maximal stimulation was observed 
with 5 ng/ml VEGF165 plus HSPG causing a 2.5 fold 
increase above control (p<O.OOl n=3). To assess that the 
observed increase in DNA synthesis was due to cell 
replication and not DNA repair, cell numbers were 
assessed over 48 hours under the same stimulatory 
conditions. VEGF165 (5-25 ng/ml) in the presence of 
HSPG stimulated a significant increase in trophoblast 
cell number (p<O.Ol, n=3) (Fig. 9B). 
HSPG potentiates VEGF 165 mediated trophoblast 
proliferation via VEGFR-2 and increased association of 
phospho-ERK 
Quiescent first trimester trophoblast cells were 
stimulated with 10 ng/ml VEGF165 premixed with 
HSPG (solid bar) alone, and in the presence of 
increasing concentrations of a neutralising anti-VEGFR-
2 antibody (ng/ml) (hatched bars) and DNA synthesis 
assessed as above. Addition of VEGF165 plus HSPG 
stimulated an increase in incorporated [3H] thymidine in 
a manner that was attenuated to control levels by 
neutralisation of VEGFR-2 (p<O.OOl, n=3, Fig. lOA). 
Potentiation of the VEGF165-VEGFR-2 downstream 
signalling pathway by HSPG was further confirmed by 
western blotting of VEGFR-1 and VEGFR-2 immuno-
precipitates with the anti-phospho-ERK antibody. 
Western blot analysis of phosphorylated ERK associated 
with VEGFR-1 or VEGFR-2 in trophoblast stimulated 
with VEGF165 alone, (solid bars) or in combination with 
HSPG (hatched bars) demonstrated a specific 42 kDa 
band in all samples (Fig. lOB). Interestingly, incubation 
with VEGFJ65 alone mediated an increase in phospho-
ERK assocIated with VEGFR-1 immunoprecipitates, 
stimulating an average 1.62 fold increase in intensity of 
the 42 kDa ERK-2 band (lanes 2, 3) (Fig. 10B,C). In 
VEGFR-2 immunoprecipitates the 42 kDa ERK-2 band 
showed no increase above control on stimulation with 
VEGF165 alone (lanes 7 and 8) (Fig. lOB,C). In contrast, 
premixing VEGF165 with HSPG prior to stimulation of 
the trophoblast with equivalent VEGF165 concentration 
attenuated the intensity of the 42 kDa band associated 
with VEGFR-l to control levels (lanes 4 and 5 as 
compared to lane 1: Fig. lOB,C). While in VEGFR-2 
immunoprecipitates the 42 kDa ERK-2 band 
demonstrated a 1.84 fold increase in intensity in samples 
stimulated with VEGF165 in the presence of HSPG (lanes 10 and 11: Fig. 10B,C). Incubation of the 
trophoblast with HSPG 40 ng/ml had no stimulatory 
effect on association of ERK above control levels in 
either VEGFR-1 (lane 6: Fig. lOB) or VEGFR-2 
immunoprecipitates (lane 12: Fig. lOB). Thus this study 
conclusively demonstrates that saturation of the 
VEGFR-l/HSPG binding domain of VEGF165 allows 
direct interaction of this isoform with VEGFR-2 
potentiating association of activated ERK to stimulate 
significant trophoblast DNA synthesis. 
Discussion 
This study provides additional evidence for an 
autocrine role for the VEGF family in trophoblast 
function from its co-localisation of VEGF-C, VEGFR-2 
and VEGFR-3 to the trophoblast in human placenta. We 
show using in vitro studies that trophoblast express 
functional VEGFR-2 and VEGFR-3 that on activation 
stimulate trophoblast proliferation and increase the 
association of phospho-ERK. Furthermore , the 
expression of VEGF-C and VEGFR-3 were decreased in 
placenta from pregnancy complicated by IUGR lending 
support to our central hypothesis that a disturbance in 
relative levels of a number of critical growth factors may 
contribute to the observed aged syncytium and poor 
angiogenesis in severe IUGR. 
The first two trimesters of placental development are 
dominated by the establishment and formation of the 
richly branched capillary beds of the mesenchymal and 
immature intermediate villi of the placenta (Kaufmann et 
aI., 1985; Leiser et aI., 1985; Demir et aI., 1989). The 
development of the villous angioarchitecture appears to 
correlate with the expression levels of VEGFR-2 
. (Vuckovic et aI., 1996) and VEGF (Jackson et aI. , 1994; 
Shirashi et aI., 1996; Khaliq et aI. , 1999) that are highest 
in early gestational placenta coinciding with the highest 
levels of cellular proliferation and angiogenesis. This 
study similarly demonstrates that high levels of VEGF-C 
and VEGFR-3 proteins were detected during early 
placental development suggesting an active role of 
VEGF-C in placental angiogenesis and villous 
development. In contrast, PlGF (Khaliq et aI., 1999) and 
VEGFR-1 (Ahmed et aI., 1995; Clark et aI., 1996) levels 
are higher during late placental development, dominated 
by non-branching angiogenesis during the formation of 
the mature intermediate and terminal villi. 
Interestingly in the term placenta both VEGF-C and 
VEGFR-3 proteins localised with highest intensity to the 
syncytiotrophoblast membrane of the terminal villi, the 
site of transport between maternal and fetal circulations. 
The lymphatic endothelium is similarly a highly 
permeable transport tissue to which VEGFR-3 
expression becomes restricted to during embryonic 
development (Kaipainen et aI., 1995). We suggest that 
VEGF-C and VEGFR-3 may playa similar role in 
trophoblast in mediating transport between the maternal 
and fetal circulations. We have previously demonstrated 
that trophoblast express both VEGF and its receptor 
VEGFR-1 (Ahmed et aI. , 1995). Addition of exogenous 
VEGF165 stimulates the release of nitric oxide via 
VEGFR-l from a first trimester trophoblast cell line 
(Ahmed et aI., 1997). In this study, the co-localisation of 
VEGF-C and both VEGFR-2 and VEGFR-3 to the 
terminally differentiated syncytiotrophoblast membrane 
lends further support to our hypothesis of an endothelial-
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like function for the syncytium (Ahmed et aI., 1995, 
1997). This suggests that like VEGF, VEGF-C may play 
an autocrine role in trophoblast cell function , in addition, 
to its paracrine effects on endothelial cells. 
In endothelial cells, both VEGFR-2 (Waltenberger et 
aI., 1994) and VEGFR-3 (Joukov et aI., 1996; Oh et aI., 
1997) were demonstrated to mediate cell proliferation 
and migration in response to VEGF and VEGF-C 
respectively. The localisation of VEGFR-2 in the 
invasive extravillous trophoblast suggests that VEGF-C 
expressed by the maternal decidua may act as a chemo-
attractant for the invasive extravillous trophoblast during 
establishment of the intervillous utero-placental 
circulation. The expression of VEGFR-2 protein in 
trophoblast of the human placenta is supported by 
studies on mice. The homologous receptor Flk-l is 
strongly expressed by trophoblast in midgestation mice 
(Millauer et aI., 1993). Previously studies on human 
placental sections reported that VEGFR-2 was restricted 
to fetoplacental endothelial cells (Vuckovic et aI., 1996). 
In the present study unmasking of the antigen, by 
microwave technique, was required to detect VEGFR-2 
protein. Vuckovic and colleagues did not use this 
procedure which explains their inability to detect 
trophoblast VEGFR-2. Moreover, mRNA encoding 
VEGFR-2 detected by RT-PCR has been reported in 
choriocarinoma cell line BeWo (Charnock Jones et aI. , 
1994), spontaneously transformed first trimester 
trophoblast ED27 (Ahmed et aI. , 1997) and in an 
extravillous trophoblast cell line (Athanassiades et aI., 
1998). 
Severe IUGR is characterised by a small sized 
placenta with abnormal morphology, demonstrating poor 
angiogenesis, increased syncytial formation, and 
erythrocyte congestion of the terminal villi (Macara et 
aI. , 1996; Krebs et aI., 1996) and suggested that there is 
"placental hyperoxia" in IUGR (Kingdom and 
Kaufmann, 1997). In this study, we demonstrate that 
both VEGF-C and VEGFR-3 proteins are significantly 
reduced in severe IUGR placenta as compared to levels 
detected in gestation ally matched third trimester 
placenta. Interestingly, like VEGF, VEGF-C was 
reported to be up-regulated during retinal ischaemia 
(Simpson et aI., 1999). Similarly, angiopoetin-2 was 
shown to be up-regulated by hypoxia in bovine 
microvascular endothelial cells (Oh et aI., 1999) and is 
also decreased in severe IUGR (Dunk et aI., 2000). 
These results are in agreement with our earlier finding 
that PIGF levels are increased in IUGR and up-regulated 
by hyperoxia (Khaliq et aI., 1999). Although these 
studies do not prove a direct causative link with 
abnormal villous development, collectively these data 
support the hypothesis of "placental hyperoxia" in severe 
IUGR. The strong association between oxygen levels 
and changes in the expression of these growth factors 
lends support to our hypothesis that increased oxygen 
levels surrounding the placental villi may limit 
angiogenesis as a result of disturbances in the expression 
and function of oxygen-sensitive angiogenic growth 
factors. 
Interestingly, levels of VEGF-C protein were found 
to be 2-fold higher in placenta obtained from labouring 
compared with non-labouring deliveries suggesting a 
potential role of VEGF-C in parturition. 'Moreover, 
VEGF-C mRNA is known to be upregulated by the 
proinflammatory cytokine IL-IB (Ristimaki et aI., 1997) 
and this cytokine plays a role in the initiation of labour 
(Kelly et aI. , 1996). Indeed the related factor VEGF has 
been demonstrated to promote parturition (Sisi et aI, 
1996). However as delivery causes hypoxia and other 
changes to the placenta it is not possible to draw a firm 
conclusion about the role of VEGF-C in the initiation of 
parturition without further studies. 
Tyrosine kinase receptors have been demonstrated to 
mediate DNA synthesis and cell proliferation through 
many signalling molecules that physically interact with 
and become activated by the receptors. Several of these 
signal transduction molecules act through the Ras and 
downstream MAP kinase pathways while others are ras-
independant (Roche et aI., 1996). In particular the 
activation and phosphorylation of the 42/44 kDa MAP 
kinase ERK-l/2 is associated with cellular proliferation 
(review Karin , 1995). This study demonstrated that 
stimulation of the trophoblast with CM containing 
VEGF-C caused an increase in phospho-ERK-2 
associated with VEGFR-3 immunoprecipitates. As stated 
earlier VEGF-C has been demonstrated to stimulate 
lymphatic endothelial cell proliferation (Fitz et aI., 
1997). This data suggests that activation of VEGFR-3 by 
VEGF-C may mediate trophoblast proliferation in 
addition to its effects on endothelium in the human 
placenta. However, as the VEGF-C protein is not yet 
commercially available, the physiological role of VEGF-
C in the human placenta and trophoblast cell function 
remains to be fully elucidated. 
It is known that VEGF165 binds to both VEGFR-l 
and VEGFR-2, but with higher affinity to VEGFR-l as it 
contains a 44 amino acid heparin binding domain 
encoded by exon seven (Terman et aI. , 1994). In 
contrast, VEGF121 binds to VEGFR-2 alone as it lacks 
the 110-165 heparinNEGFR-l binding domain (Gitay-
Goren et aI., 1996; Keyt et aI., 1996a,b). The present 
study demonstrates that VEGF121 stimulated a dose-
dependant phosphorylation of the 210 kDa band in 
VEGFR-2 immunoprecipates from the first trimester 
trophoblast. The 210 kDa band detected represents direct 
auto-phosphorylation of VEGFR-2, and is in agreement 
with molecular weights reported previously for 
autophosphorylation (Waltenberger et aI. , 1994; Thieme 
et aI., 1995) and receptor-ligand cross-linking studies 
(Thieme et aI. , 1995; Gitay-Goren et aI., 1996). The 
observed increase in phosphorylation of the 210 kDa 
VEGFR-2 band at all concentrations of VEGF121 
represents direct interaction of this isoform with 
VEGFR-2 while VEGF165 had little effect. It has been 
proposed that the dose dependancy of VEGF165 
interaction with VEGFR-2 in trophoblast cells may be 
influenced by the competitive binding with VEGFR-l or 
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cell surface HSPG (Athanassiaides et ai. , 1998). In 
particular heparin is demonstrated to potentiate the 
binding of VEGF to the extracellular domains of soluble 
or endothelial cell associated KD R/Flk -1 (Tessler et aI., 
1994; Roeckl et aI., 1998). Moreover, VEGF165 is 
thought to mediate endothelial cell proliferation through 
specific activation of VEGFR-2 (WaJtenberger et aI. , 
1994). This study demonstrates that premixing VEGF 
with HSPG stimulated a significant increase in 
trophoblast proliferation and increased association of 
phospho-ERK with VEGFR-2 immunoprecipitates. 
Moreover, neutralisation of the VEGFR-2 receptor 
inhibited VEGF165 mediated trophoblast DNA synthesis 
to control levels. Thus , this study conclusively 
demonstrates that VEGF stimulated trophoblast 
proliferation via activation of VEGFR-2 , as in 
endothelial cells. 
VEGF121 also stimulated an increase of a 120 and 
130 kDa phospho-protein associated with VEGFR-2. In 
addition to direct autophosphorylation of its receptors, 
VEGF is known to induce the tyrosine phosphorylation 
of a variety of intracellular mediators of signal 
transduction containing src homology 2 (SH2) domains 
(Waltenberger et aI., 1994; Guo et aI., 1995; Landgren et 
ai. , 1998). Among these , a 120 kDa Ras GTPase 
(RasGAP) is thought to be important in mediating 
endothelial cell chemotaxis (Kundra et aI., 1994), 
suggesting that VEGF may mediate trophoblast function 
via a GAP-mediated mechanism . The 130 kDa 
phosphorylated protein associated with VEGFR-2 
immunoprecipitates is as yet unidentified, though other 
studies have demonstrated the common association of 
this band with VEGFR-1 on stimulation with both 
VEGF and PlGF, and VEGFR-2 on stimulation with 
VEGF (Landgren et aI., 1998). 
This study demonstrates the co-localisation of 
VEGFR-2 and VEGFR-3 and their novel ligand VEGF-
C in placental cells of both non-endothelial and 
endothelial types suggesting a dual autocrine and 
paracrine role for VEGF family during placental 
angiogenesis and villous development. In support of an 
autocrine role, we have demonstrated the presence of 
functional VEGFR-2 and VEGFR-3 in first trimester 
human trophoblast by linking the respective receptor 
signalling to activation and association of the ERK-2 
phospho-protein and cell proliferation. Moreover, this 
study provides further evidence of abnormal growth 
factor expression in severe IUGR placenta and its's 
association with placental hyperoxia. Both VEGF-C and 
VEGFR-3 protein levels were significantly decreased in 
severe IUGR and thus may contribute to the disturbances 
in trophoblast and endothelial cell proliferation and 
function. In conclusion, this data together with earlier 
studies (Ahmed and Kilby, 1997; Khaliq et aI., 1999; 
Dunk et aI., 2000) indicates that increased oxygen levels 
surrounding the placental villi may limit angiogenesis 
and villous development as a result of disturbances in 
the expression and function of oxygen-sensitive 
angiogenic growth factors. 
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